Methods of suppressing hepatitis virus infection using...

Details Methods of suppressing hepatitis virus infection using... Methods of suppressing hepatitis virus infection using...

2003-02-03

2010-06-01

Le, Emily M. (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving virus or bacteriophage

C424S278100, C424S184100

Reexamination Certificate

active

07727712

ABSTRACT:
Methods are provided for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. A polynucleotide comprising an immunostimulatory sequence is administered to a individual who has been exposed to or infected by HBV and/or HCV. The polynucleotide is not administered with a HCV or HBV antigen. Administration of the polynucleotide results in amelioration of symptoms of HBV and/or HCV infection.

REFERENCES:
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4849513 (1989-07-01), Smith et al.
patent: 4910300 (1990-03-01), Urdea et al.
patent: 4948882 (1990-08-01), Ruth
patent: 5015733 (1991-05-01), Smith et al.
patent: 5093232 (1992-03-01), Urdea et al.
patent: 5118800 (1992-06-01), Smith et al.
patent: 5118802 (1992-06-01), Smith et al.
patent: 5124246 (1992-06-01), Urdea et al.
patent: 5453496 (1995-09-01), Caruthers et al.
patent: 5616461 (1997-04-01), Schaffer et al.
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 5849719 (1998-12-01), Carson et al.
patent: 5874089 (1999-02-01), Schlegel et al.
patent: 6174872 (2001-01-01), Carson et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6339068 (2002-01-01), Krieg et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6498148 (2002-12-01), Raz
patent: 6514948 (2003-02-01), Raz et al.
patent: 6534062 (2003-03-01), Raz et al.
patent: 6552006 (2003-04-01), Raz et al.
patent: 6613751 (2003-09-01), Raz et al.
patent: 7157437 (2007-01-01), Van Nest
patent: 2001/0046967 (2001-11-01), Van Nest
patent: 2002/0028784 (2002-03-01), Nest
patent: 2002/0098199 (2002-07-01), Van Nest et al.
patent: 2002/0107212 (2002-08-01), Nest et al.
patent: 2003/0050263 (2003-03-01), Krieg et al.
patent: 2003/0092663 (2003-05-01), Raz
patent: 2004/0009942 (2004-01-01), Van Nest
patent: 2004/0030118 (2004-02-01), Wagner et al.
patent: 2005/0059626 (2005-03-01), Van Nest et al.
patent: 2005/0101554 (2005-05-01), Krieg et al.
patent: 2007/0060540 (2007-03-01), Van Nest
patent: 468520 (1992-01-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 97/28259 (1997-08-01), None
patent: WO 98/16247 (1998-04-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/52962 (1998-11-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55609 (1998-12-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 99/33488 (1999-07-01), None
patent: WO 99/33488 (1999-07-01), None
patent: WO 99/33868 (1999-07-01), None
patent: WO 99/33868 (1999-07-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/56755 (1999-11-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 00/06588 (2000-02-01), None
patent: WO 00/16804 (2000-03-01), None
patent: WO 00/21556 (2000-04-01), None
patent: WO 00/62802 (2000-10-01), None
patent: WO 00/62802 (2000-10-01), None
patent: WO 00/67023 (2000-11-01), None
patent: WO 01/02007 (2001-01-01), None
patent: WO 01/12223 (2001-02-01), None
patent: WO 01/55341 (2001-08-01), None
patent: WO 01/55341 (2001-08-01), None
patent: WO 01/68077 (2001-09-01), None
patent: WO 01/68077 (2001-09-01), None
patent: WO-01/68078 (2001-09-01), None
patent: WO-01/68078 (2001-09-01), None
patent: WO 01/68103 (2001-09-01), None
patent: WO 01/68103 (2001-09-01), None
patent: WO 01/68116 (2001-09-01), None
patent: WO 01/68116 (2001-09-01), None
patent: WO 01/68117 (2001-09-01), None
patent: WO 01/68117 (2001-09-01), None
patent: WO 01/68143 (2001-09-01), None
patent: WO 01/68143 (2001-09-01), None
patent: WO 01/68144 (2001-09-01), None
patent: WO 01/68144 (2001-09-01), None
patent: WO 01/76642 (2001-10-01), None
De Francesco et al. Challenges and successes in developing new therapies of hepatitis C. Nature, 2005, vol. 436, 953-960.
Hahn. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Current opinion in Immunology, 2003, vol. 15, 443-449.
Knipe DM, Howley PM, eds. Fields virology. 4th ed. vol. 1. Philadelphia: Lippincott Williams & Wilkins, 2001, 1004-1016 and 1127-1161.
Mutwiri et al. Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Veterinary Immunology and Immunopathology, 2003, vol. 91, 89-103.
Krieg et al. CpG motif in bacterial DNA and their immune effects. Annu. Rev. Immunol., 2002, vol. 20, 709-760.
Fearon et al. A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production. Eur J. Immunol., Aug. 2003, vol. 33, No. 8, 2114-2122.
Agrawal, S. and Kandinalla, E.R. (2002). “Medicinal Chemistry and Therapeutic Potential of CpG DNA,”Trends in Molecular Medicine8(3):114-121.
Ausubel Frederick M. et al., eds. (1995).Current Protocols in Molecular Biology. vol. 1, John Wiley & Sons, Inc.: pp. iii-xii (Table of Contents).
Ballas, Zuhair et al. (1996). “Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA”J. Immunol.157:1840-1845.
Beaucage, Serge L. (1993). “Oligodeoxyribonucleotide Synthesis” vol. 20 Chapter 3in Protocols for Oligonucleotides and Analogs, Synthesis and Properties, Agrawal (ed.), Humana Press: Totowa, NJ. pp. 33-61.
Branda, Richard F. et al. (1993). “Immune Stimulation by an Antisense Oligomer Complementary to the Rev Gene of HIV-1”Biochem. Pharmacol.45(10):2037-2043.
Branda, Richard F. et al. (1996). “Amplification of Antibody Production by Phosphorothioate Oligodeoxynucleotides”J. Lab. Clin. Med.128(3):329-338.
Braun, Ralph P. and Lee, Jeremy S. (1988). “Immunogenic Duplex Nucleic Acids are Nuclease Resistant” J. Immunol. 141(6):2084-2089.
Brazolot Millan, Cynthia L. et al. (1998). “CpG DNA can Induce Strong Th1 Humoral and Cell-Mediated Immune Responses Against Hepatitis B Surface Antigen in Young Mice”Proc. Natl. Acad. Sci. USA95:15553-15558.
Broide, David et al. (1998). “Immunostimulatory DNA Sequences Inhibit IL-5, Eosinophilic Inflammation, and Airway Hyperresponsiveness in Mice”J. Immunol.161:7054-7062.
Broide, David and Raz, Eyal (1999). “DNA-Based Immunization for Asthma”Int. Arch. Allergy Immunol.118:453-456.
Carson, Dennis A. and Raz, Eyal (1997). “Oligonucleotide Adjuvants for T Helper 1 (Th1)-Specific Vaccination”J. Exp. Med.186(10):1621-1622.
Chace, Jacqueline H. et al. (1997). “Bacterial DNA-Induced NK Cell IFN-Gamma Production is Dependent on Macrophage Secretion of IL-12”Clin. Immunol. and Immunopathol.84(2):185-193.
Chaturvedi, Surendra et al. (1996). “Stabilization of Triple-Stranded Oligonucleotide Complexes: Use of Probes Containing Alternating Phosphodiester and Stereo-Uniform Cationic Phosphoramidate Linkages”Nucleic Acids Res.24(12):2318-2323.
Chu, Rose S. et al. (1997). “CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity”J. Exp. Med.186(10):1623-1631.
Coligan, John E. et al., eds. (1998).Current Protocols in Immunologyvol. 1, John Wiley & Sons, Inc: pp. 1-9 (Table of Contents).
Cowdery, John S. et al. (1996). “Bacterial DNA Induces NK Cells to Produce IFN-Gamma in Vivo and Increases the Toxicity of Lipopolysaccharides”J. Immunol.156:4570-4575.
Dartmann et al. (1986). “The Nucleotide Sequence and Genome Organization of Human Papilloma Virus Type 11,”Virology151:124-130.
Davis, H. et al. (1998). “CpG DNA is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen,”Journal of Immunology160(2):870-876.
Dolin. (1985). “Antiviral Chemotherapy and Chemoprophylaxis,”Science227:1296-1303.
Elkins, Karen L. et al. (1999). “Bacterial DNA Containing CpG Motifs Stimulates Lym

Affiliated with

Also associated with

Rating

Methods of suppressing hepatitis virus infection using... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of suppressing hepatitis virus infection using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of suppressing hepatitis virus infection using... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4245009